Taking into account the knowledge obtained from in vitro and in silico assays, further studies can be carried out to design a new series of PTs with improved EGFR inhibitory potency by the structural modification of compound 10 and investigate not only their direct cytotoxic effects on GBM cells but also their effects on the tumor microenvironment (e.g., suppression of angiogenesis, tumor-related inflammation, etc.). This evidence concerns the gene EGFR and neoplasm.